Taken together, this study suggests that enhancing SIK1 activity with ZQR would be expected to decrease hyperglycemia and hyperlipidemia as well as hepatic lipid storage in patients with diabetes with NAFLD. Here, SIK1 is linked to diabetes mellitus.